HS-20093 + bevacizumab + capecitabine

HS-20093 + bevacizumab + capecitabine is a combination investigational therapy comprising three agents: - **HS-20093** is a fully humanized IgG1 antibody-drug conjugate targeting B7-H3 (CD276), a molecule highly expressed on solid tumors, and is conjugated to a topoisomerase inhibitor payload. It acts by binding B7-H3 and delivering the cytotoxic agent directly to tumor cells[1][3][5][7]. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby restricting tumor blood supply[2][6][8]. - **Capecitabine** is a prodrug of 5-fluorouracil, functioning as an oral chemotherapeutic antimetabolite that inhibits DNA synthesis in proliferating cells[6]. This regimen is currently under investigation primarily in advanced or refractory solid tumors such as small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sarcoma, and colorectal cancer[1][3][5][7]. Trials are ongoing in China, and the combination is considered experimental with promising early anti-tumor activity and manageable toxicity profiles.

Brand names

Xeloda (for capecitabine)No unique brand name for this triple combination

Other names

GSK5764227 (for HS-20093)GSK’227 (for HS-20093)